Publication:
HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients

Simple item page
dc.contributor.authorMarjanu Hikmah Eliasen_US
dc.contributor.authorAbdul Aziz Babaen_US
dc.contributor.authorAzlan Husin Sarina Sulongen_US
dc.contributor.authorRosline Hassanen_US
dc.contributor.authorGoh Ai Simen_US
dc.contributor.authorS Fadilah Abdul Wahiden_US
dc.contributor.authorRavindran Ankathilen_US
dc.date.accessioned2024-05-27T15:01:04Z
dc.date.available2024-05-27T15:01:04Z
dc.date.issued2013
dc.descriptionVolume 2013en_US
dc.description.abstractDevelopment of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients has emerged as a significant clinical problem. The observation that increased epigenetic silencing of potential tumor suppressor genes correlates with disease progression in some CML patients treated with IM suggests a relationship between epigenetic silencing and resistance development. We hypothesize that promoter hypermethylation of HOXA4 could be an epigenetic mechanism mediating IM resistance in CML patients. Thus a study was undertaken to investigate the promoter hypermethylation status of HOXA4 in CML patients on IM treatment and to determine its role in mediating resistance to IM. Genomic DNA was extracted from peripheral blood samples of 95 CML patients (38 good responders and 57 resistant) and 12 normal controls. All samples were bisulfite treated and analysed by methylation-specific high-resolution melt analysis. Compared to the good responders, the HOXA4 hypermethylation level was significantly higher (P = 0.002) in IM-resistant CML patients. On comparing the risk, HOXA4 hypermethylation was associated with a higher risk for IM resistance (OR 4.658; 95% CI, 1.673-12.971; P = 0.003). Thus, it is reasonable to suggest that promoter hypermethylation of HOXA4 gene could be an epigenetic mechanism mediating IM resistance in CML patients.en_US
dc.identifier.doi10.1155/2013/129715
dc.identifier.epage7
dc.identifier.issn2314-6133
dc.identifier.spage1
dc.identifier.urihttps://www.hindawi.com/journals/bmri/2013/129715/
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/4057
dc.identifier.volume2013
dc.language.isoen_USen_US
dc.publisherHindawi Publishing Corporationen_US
dc.relation.ispartofBioMed Research Internationalen_US
dc.titleHOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.pdf
Size:
2.08 MB
Format:
Adobe Portable Document Format
Download

Collections

Other Publications